1. Home
  2. ARTL vs JAGX Comparison

ARTL vs JAGX Comparison

Compare ARTL & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • JAGX
  • Stock Information
  • Founded
  • ARTL 2011
  • JAGX 2013
  • Country
  • ARTL United States
  • JAGX United States
  • Employees
  • ARTL N/A
  • JAGX N/A
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • JAGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARTL Health Care
  • JAGX Health Care
  • Exchange
  • ARTL Nasdaq
  • JAGX Nasdaq
  • Market Cap
  • ARTL 3.1M
  • JAGX 3.4M
  • IPO Year
  • ARTL N/A
  • JAGX N/A
  • Fundamental
  • Price
  • ARTL $13.73
  • JAGX $2.24
  • Analyst Decision
  • ARTL Strong Buy
  • JAGX Strong Buy
  • Analyst Count
  • ARTL 2
  • JAGX 1
  • Target Price
  • ARTL $25.00
  • JAGX $60.00
  • AVG Volume (30 Days)
  • ARTL 1.9M
  • JAGX 99.7K
  • Earning Date
  • ARTL 08-12-2025
  • JAGX 08-12-2025
  • Dividend Yield
  • ARTL N/A
  • JAGX N/A
  • EPS Growth
  • ARTL N/A
  • JAGX N/A
  • EPS
  • ARTL N/A
  • JAGX N/A
  • Revenue
  • ARTL N/A
  • JAGX $11,552,000.00
  • Revenue This Year
  • ARTL N/A
  • JAGX $22.41
  • Revenue Next Year
  • ARTL N/A
  • JAGX $30.00
  • P/E Ratio
  • ARTL N/A
  • JAGX N/A
  • Revenue Growth
  • ARTL N/A
  • JAGX 13.93
  • 52 Week Low
  • ARTL $4.92
  • JAGX $2.19
  • 52 Week High
  • ARTL $28.60
  • JAGX $35.25
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 50.80
  • JAGX 29.03
  • Support Level
  • ARTL $12.67
  • JAGX $2.32
  • Resistance Level
  • ARTL $16.44
  • JAGX $2.79
  • Average True Range (ATR)
  • ARTL 3.50
  • JAGX 0.14
  • MACD
  • ARTL -0.75
  • JAGX 0.08
  • Stochastic Oscillator
  • ARTL 6.65
  • JAGX 8.33

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: